Topoisomerase-I inhibitors in gynaecologic tumours.
Copyright policy )Topoisomerase-I inhibitors in gynaecologic tumours.
Topoisomerase inhibitors have been studied using various dose schedules in the treatment of refractory or recurrent gynaecologic cancers. Response rates are between 13% and 20%. Main toxic effects are haematologic and gastrointestinal. The latter remains problematic. Radiotherapy, alkylate, platinum analogs and topoisomerase II inhibitors are currently being studied in combination with camptothecins.
Ovarian Neoplasms, Humans, Uterine Cervical Neoplasms, Antineoplastic Agents, Female, Enzyme Inhibitors, Neoplasm Recurrence, Local, Topoisomerase I Inhibitors, Combined Modality Therapy
Ovarian Neoplasms, Humans, Uterine Cervical Neoplasms, Antineoplastic Agents, Female, Enzyme Inhibitors, Neoplasm Recurrence, Local, Topoisomerase I Inhibitors, Combined Modality Therapy
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!